Eric Suan, MD
Ophthalmology · Baltimore, MDNPI 1275536971
Payments from drug & device makers
Across 1,006 payments — averaging $6836.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$3.1M
- Genentech, Inc.$2.8M
- Bayer$409K
- Apellis Pharmaceuticals, Inc.$307K
- Regeneron$93K
- Eyepoint US, Inc.$63K
- plus $105K from 14 others
Across 10 payments — averaging $166.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 17 | $3,069,282 |
| Genentech, Inc. | 361 | $2,831,394 |
| Bayer | 170 | $408,573 |
| Apellis Pharmaceuticals, Inc. | 191 | $307,258 |
| Regeneron | 45 | $92,672 |
| Eyepoint US, Inc. | 17 | $63,245 |
| Amgen | 6 | $46,636 |
| Janssen Research & Development, LLC | 21 | $17,855 |
| AbbVie(2 entities) | 34 | $14,117 |
| Regeneron Healthcare Solutions, Inc. | 72 | $11,937 |
| Genentech USA, Inc. | 44 | $11,320 |
| Astellas Pharma US Inc | 7 | $2,559 |
| Alimera Sciences, Inc. | 8 | $167 |
| Coherus Oncology, Inc. | 3 | $92 |
| Bausch & Lomb Americas Inc. | 4 | $78 |
| Alcon | 1 | $66 |
| Sandoz | 2 | $63 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Spark Therapeutics, Inc. | 1 | $12 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $12 |
How this compares
$6,877,363 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Baltimore
- Daniel FinkelsteinBaltimore$6.9M
- Peter CampochiaroBaltimore$5.4M
- Neil BresslerBaltimore$3.6M
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- John ThompsonBaltimore$1.8M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$1.1M
- Earl CravenBaltimore$315K
- Akosua NtiBaltimore$315K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.